Search our news archive and pharma companies…
|
Today's News | Note: News feeds may no longer be available for the articles on this page.
Cephalon
Boosts Price Of Top Drug 29% Amid Switch Effort 7:35 AM 12/22/2009
Wall Street Journal
Cephalon Inc raised the price of its Provigil stimulant to
encourage patients to switch to a longer-lasting successor Nuvigil before the original loses patent protection
in 2012.
...
Vical
says gets US patent for herpes DNA vaccine 6:16 AM 12/22/2009
Reuters
Vical Inc said the company and the University of Washington have received
a US patent covering DNA vaccines for a type of sexually transmitted virus causing of genital herpes.
...
FDA
delays decision on Cephalon drug for jet lag 4:51 PM 12/21/2009
Reuters
The US FDA has delayed a decision on Cephalon Inc's sleep disorder drug
Nuvigil to treat sleepiness caused by jet lag. The drug is already approved for patients who suffer from
excessive sleepiness due to sleep apnea, narcolepsy, or shift work disorder.
...
OncoGenex,
Teva in deal for cancer therapy 8:21 AM 12/21/2009
Reuters
OncoGenex Pharmaceuticals and Teva Pharmaceutical Industries reach licensing deal for
cancer therapy OGX-011 co-developed with Isis Pharmaceuticals.
...
CTI
says cancer drug gets orphan status in Europe 7:20 AM 12/21/2009
Reuters
Cell Therapeutics Inc said European health regulators granted orphan drug
designation for its experimental drug pixantrone in Europe for the treatment of diffuse large B-Cell lymphoma.
...
Incyte
Licenses Drug to Eli Lilly 6:51 AM 12/21/2009
TheStreet.com
Incyte announced it has licensed a mid-stage rheumatoid arthritis drug to Eli
Lilly which is paying $90 million upfront for development and marketing rights to INCB28050 currently in phase
II study for rheumatoid arthritis.
...
Sanofi to buy Chattem for $1.9 billion in OTC push 6:16 AM
12/21/2009
MarketWatch
Sanofi-Aventis struck a deal to buy Chattem Inc for
$1.9 billion in a bid to expand its presence in over-the-counter and consumer brands. Sanofi will pay a 44%
premium to the shares' six-month average price.
...
Sanofi
stops development of two drugs 5:30 AM 12/21/2009
Reuters
Sanofi-Aventis stopped developing two drugs to overhaul of its research and
development portfolio. The US FDA granted a speedier approval for Sanofi's cabazitaxel as a second-line
treatment for prostate cancer.
...
UCB
says Crohn's test fails to prove drug 3:36 AM 12/21/2009
Reuters
UCB conducted Phase IIIb testing of its drug Cimzia to assess its efficacy and safety
in patients with moderate to severe Crohn's disease yielded poor results.
...
Safety
worries hit Actelion's key sleep drug 2:21 AM 12/21/2009
Reuters
Actelion said safety observations on insomnia drug almorexant could not be detailed
until longer-term data were available.
...
Say
No To Counterfeit Drugs 7:13 AM 12/19/2009
Forbes
Obama opposes importation on safety grounds. So did Bush and Clinton. Message to
Dorgan. A dumb idea is a dumb idea.
...
Myriad
Pharmaceuticals Acquires a Drug Maker 5:56 PM 12/18/2009
New York Times
Myriad Pharmaceuticals agreed to buy Javelin Pharmaceuticals in a deal worth
about $96 million to acquire its postoperative pain drug Dyloject.
...
Ligand,
Glaxo drug closer to European approval 9:31 AM 12/18/2009
Forbes
Ligand Pharmaceuticals Inc said a European advisory committee recommended approval of
the blood disorder treatment Revolade (eltrombopag; approved in the US as Promacta).
...
EU
agency recommends Novartis meningitis vaccine 6:54 AM 12/18/2009
Reuters
The European Medicines Agency backed use of Menveo for meningitis
immunization of adolescents and adults at risk of exposure. The US FDA may rule on Menveo in early 2010.
...
European
panel recommends Amgen, Glaxo bone drug 6:50 AM 12/18/2009
Reuters
Amgen's new osteoporosis drug denosumab has been recommended for approval
in Europe. GlaxoSmithKline will help commercialize the potential billion dollar biotech bone drug in Europe.
...
<- Day Earlier | Today's News
|
